SASS ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 36 | Epidermolysis bullosa | 1 |
36. Epidermolysis bullosa
Clinical trials : 163 / Drugs : 185 - (DrugBank : 46) / Drug target genes : 50 - Drug target pathways : 125
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04171661 (ClinicalTrials.gov) | December 10, 2019 | 19/11/2019 | Self-Assembled Skin Substitute for the Treatment of Epidermolysis Bullosa | SASS 3: Self-Assembled Skin Substitute (SASS) for the Treatment of Epidermolysis Bullosa | Epidermolysis Bullosa Dystrophica | Biological: SASS | CHU de Quebec-Universite Laval | The Hospital for Sick Children | Active, not recruiting | N/A | N/A | All | 1 | Early Phase 1 | Canada |